Juan Luciano
Chief Executive Officer
Yes. Thank you, Ben. Good question. We are maintaining our balanced capital allocation that we put together some years back. We always said that we're going to take about 30% to 40% of our free cash flow to reinvest in the business, and that's what our strategy of bolt-on and organic growth normally takes. And that will be the priority. We have exciting opportunities ahead of us. So we're going to prioritize our investment plan. But of course, we've been paying dividends for 90 years. We've been growing dividends for more than 40 years, and we will continue that. We increased dividends 8% this year. And when we're looking at our distribution, again, this 60% to 70%, whether there are strategic opportunities to do M&A or giving back to shareholders, as we said before, at this point in time, when valuations may be correcting and all that, we don't have any significant targets in front of us. Our team continue to look for bolt-ons. And given the significant strength of our cash flows, we have decided to honor that return of shareholder -- of funds to shareholders. So I would say we will maintain that balanced allocation. We are not -- in the plan when we presented in December, we were looking at the later part of the plan as we were approaching $6 to $7 per share that we will have ability to repurchase about $5 billion of that. Certainly, we will be, as I said in my initial remarks, north of $6.50 today. So some of those buybacks are accelerated to the scenario. So I would say it continues to be consistent in that regard. Is there a later part of the question I'm missing or forgetting? Oh, the capacity to increase, yes, organic capacity. Listen, we are -- as you can -- Vikram mentioned it, we are increasing our CapEx into $1.3 billion. And we've been accelerating some long lead equipment this year to make sure that our capacity expansions remain on schedule. So if we look at the big ones that we have right now, whether it's Spiritwood, it's still expected to be online by the harvest of 2023. We are expanding capacity in bioactives in Valencia. That's expected to come in the first quarter of 2023. That's also on schedule. So I would say, in general, across the globe, since we have the ability and the funds, we've been making sure that we eliminated that risk or we minimized that risk. Of course, there is always a risk of labor and labor is tight, especially in North America. But I think at this point in time, we don't have any major deviation to our plans.